Michail D. Drakomathioulakis

Mr. Michail D. Drakomathioulakis

Cath Lab, Cardiology Department, Nicosia General Hospital, Nicosia, Lefkosía, Cyprus
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ANDREAS MITSISANDREAS MITSIS
ANDREAS MITSIS
SSStefanos Sokratous
Stefanos Sokratous
GKGeorgia Karmioti
Georgia Karmioti
MKMichaela Kyriakou
Michaela Kyriakou
Michail D. DrakomathioulakisMichail D. Drakomathioulakis
Michail D. Drakomathioulakis
GKGeorge Kassimis
George Kassimis
C-reactive protein (CRP) has emerged as a valuable biomarker in acute myocardial infarction (AMI), offering multiple insights into diagnosis, prognosis, and therapeutic strategies. In the diagnostic domain, elevated CRP levels serve as an early indicator of AMI, aiding in prompt identification and initiation of treatment. Prognostically, CRP is a strong predictor of adverse outcomes post-AMI, correlating with increased mortality and cardiovascular events. Beyond its diagnostic and prognostic roles, CRP also exposes therapeutic avenues in AMI management. Targeting CRP through pharmacological interventions has shown promise in reducing inflammatory responses, thereby mitigating myocardial damage and improving clinical outcomes. However, CRP’s low specificity, influenced by elevation in non-cardiac conditions, remains a clinical limitation that warrants consideration. This review comprehensively examines the evolving role of CRP in AMI, exploring its diagnostic accuracy, prognostic significance, and potential as a therapeutic target. The understanding of the complex role of CRP in AMI provides clinicians with valuable tools for risk stratification, treatment optimization, and personalized patient care in the acute setting.

26 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ANDREAS MITSISANDREAS MITSIS
ANDREAS MITSIS
MMMichael Makarios Myrianthefs
Michael Makarios Myrianthefs
SSStefanos Sokratous
Stefanos Sokratous
GKGeorgia Karmioti
Georgia Karmioti
MKMichaela Kyriakou
Michaela Kyriakou
GKGeorge Kassimis
George Kassimis
Acute coronary syndrome (ACS) remains a major cause of morbidity and mortality worldwide, requiring ongoing efforts to identify novel therapeutic targets to improve patient outcomes. This manuscript reviews promising therapeutic targets for ACS identified through preclinical research, including novel antiplatelet agents, anti-inflammatory drugs, and agents targeting plaque stabilization. Preclinical studies have expounded these agents’ efficacy and safety profiles in mitigating key pathophysiological processes underlying ACS, such as platelet activation, inflammation, and plaque instability. Furthermore, ongoing clinical trials are evaluating the efficacy and safety of these agents in ACS patients, with potential implications for optimizing ACS management. Challenges associated with translating preclinical findings into clinical practice, including patient heterogeneity and trial design considerations, are also discussed. Overall, the exploration of emerging therapeutic targets offers promising avenues for advancing ACS treatment strategies and improving patient outcomes.

21 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ANDREAS MITSISANDREAS MITSIS
ANDREAS MITSIS
MKMichaela Kyriakou
Michaela Kyriakou
SSStefanos Sokratous
Stefanos Sokratous
GKGeorgia Karmioti
Georgia Karmioti
Michail D. DrakomathioulakisMichail D. Drakomathioulakis
Michail D. Drakomathioulakis
GKGeorge Kassimis
George Kassimis
The role of inflammation in the pathophysiology of acute myocardial infarction (AMI) is well established. In recognizing inflammation’s pivotal role in AMI, this manuscript systematically traces the historical studies spanning from early attempts to the present landscape. Several anti-inflammatory trials targeting inflammation in post-AMI have been performed, and this review includes the key trials, as well as examines their designs, patient demographics, and primary outcomes. Efficacies and challenges are analyzed, thereby shedding light on the translational implications of trial outcomes. This article also discusses emerging trends, ongoing research, and potential future directions in the field. Practical applications and implications for clinical practice are considered by providing a holistic view of the evolving landscape of anti-inflammatory interventions in the context of AMI.

27 February 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ANDREAS MITSISANDREAS MITSIS
ANDREAS MITSIS
MKMichaela Kyriakou
Michaela Kyriakou
SSStefanos Sokratous
Stefanos Sokratous
GKGeorgia Karmioti
Georgia Karmioti
Michail D. DrakomathioulakisMichail D. Drakomathioulakis
Michail D. Drakomathioulakis
GKGeorge Kassimis
George Kassimis
The role of inflammation in the pathophysiology of acute myocardial infarction (AMI) is well established. Recognizing inflammation's pivotal role in AMI, this manuscript systematically traces historical studies, spanning from early attempts to the present landscape. Several anti-inflammatory trials targeting inflammation in post-AMI have been performed. The review includes key trials, examining their designs, patient demographics, and primary outcomes. Efficacy and challenges are analyzed, shedding light on the translational implications of trial outcomes. The article also discusses emerging trends, ongoing research, and potential future directions in the field. Practical applications and implications for clinical practice are considered, providing a holistic view of the evolving landscape of anti-inflammatory interventions in the context of AMI.